Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2020

View Archived Issues

CSL begins phase II study of CSL-346 in diabetic kidney disease

Optimization of selective TLR7/TLR8 dual antagonists using a new antagonist competition assay

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Roche opens enrollment in phase III studies of crovalimab for PNH

New phase I/II study evaluates melanoma peptide vaccine with adjuvants

FDA approves Simponi Aria for pJIA and PsA in pediatric patients

Sorrento and ViralClear to explore combination therapy against COVID-19

FDA accepts IND application for phase IIb/III study of mesdopetam in PD-LIDs

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology patent BTK inhibitors

Macrophage migration inhibitory factor inhibitors discovered at Immunophage Biomedical

Alterity Therapeutics identifies compounds that modulate biological metals

Zhejiang Huahai Pharmaceutical, Shanghai Synergy Pharmaceutical Sciences disclose JAK inhibitors

AbbVie, Calico Life Sciences discover PTPN1/2 inhibitors

Enrollment begins in phase I/II study of 4D-310 gene therapy

Stem cells can help stem Klebsiella infection

Phase I study results with ST-617 for oral mucositis lead to phase II planning

Results from JAVELIN Head & Neck 100: avelumab fails in combination with chemoradiation

Overall survival data presented from phase III from SOLAR-1 study of alpelisib plus fulvestrant

Baylx gets IND approval to conduct study of BX-U001 in patients with COVID-19

Survival not improved with vandetanib added to fulvestrant in metastatic ER+ breast cancer

FDA clears IND for phase I studies of TNB-486 in B-cell malignancies

IntraBio's multinational trial of IB-1001 in Niemann-Pick disease type C meets primary endpoint

FDA lifts clinical hold on Solid's phase I/II study of SGT-001 in DMD

FDA issues complete response letter for remestemcel-L in pediatric steroid-refractory acute GvHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...